Scope Fluidics – a life-science company listed on the Warsaw Stock Exchange (GPW) that develops innovative technologies for the medical diagnostics and healthcare markets – held more than PLN 138 million in cash and cash equivalents at the close of Q1 2025.
In the first quarter, the Group met the first of its strategic targets (regarding the number of projects and special-purpose vehicles) and is now advancing three SPVs: BACTEROMIC, scheduled to debut on the European market this year, and two new companies spun out of Scope Discovery – EDOCERA and HYBOLIC. Scope Fluidics plans to intensify investments tied to ongoing projects and business scaling.
“The opening months of the year were devoted to intensive planning and to actions centered on advancing our key projects. Our top priority is BACTEROMIC – we are working hard to make it our next commercial success following Curiosity Diagnostics, which we sold for a total of USD 130 million. We are systematically enhancing the value of the BACTEROMIC system, which delivers precise information on the antibiotics most effective for treating bacterial infections. Early Access Program results confirmed the solution’s readiness for commercialization. We are pursuing certification under IVDR requirements, and in May we filed a pre-submission with the U.S. FDA for the BACTEROMIC system with the Rapid UNI Panel. We are also investing in a semi-automated production line for BACTEROMIC panels being developed in partnership with an NYSE-listed global industrial-technology leader. Over the coming months we will further intensify work on our flagship project and related key investments. Continuous investment in our projects is how we execute our strategy – to sell our innovative solutions on a regular basis,” said Piotr Garstecki, CEO of Scope Fluidics.
In Q1 the Group achieved the first milestone of the Scope Fluidics Development Strategy ahead of schedule. The strategy envisaged that by the end of 2025 the Company would have at least five new projects in its portfolio, including at least two structured as SPVs.
Scope Fluidics is currently developing two new projects within SPVs: 1) EDOCERA – a system designed for rapid diagnosis of stroke onset; 2) HYBOLIC – a system intended for early detection of metabolic-syndrome risk, leading among other outcomes to insulin resistance and type 2 diabetes, by quantifying key biomarkers, including hormones.
Project generation and early development are handled by Scope Discovery – an in-house venture-studio organization responsible for creating and advancing new projects in a repeatable, structured model. As of the end of Q1 2025, 48 projects had been registered for evaluation within Scope Discovery: 17 have been closed, 13 are in progress, and another 16 are awaiting assessment.
Intensifying Investment in a Challenging Environment
At the end of Q1 2025 the Group held more than PLN 138 million in cash and cash equivalents (approximately PLN 116 million in cash and bank balances and approximately PLN 22 million in investment-fund units).
“We currently allocate the bulk of our capital-expenditure budget to developing Bacteromic as we prepare it for a potential M&A transaction. Investing in advanced technologies is a long-term process that requires specialist knowledge, a strong expert base, and prudent yet flexible financial management – an approach we have followed for years. In the face of geopolitical and market uncertainty, maintaining a strong cash position is essential to reinforce our negotiating stance and maximize value for stakeholders. We are fully aware that sizable investments lie ahead, shaping the Company’s future over the coming years. To expand our financing options, we have proposed that shareholders authorize the Management Board to issue up to 680 thousand new shares under authorized capital. We are also analyzing other available options,” noted Szymon Ruta, Vice President and CFO of Scope Fluidics.
Management estimates that achieving Group Objectives for 2025–2027 will require total funding of roughly PLN 240 million (including outlays already incurred since the start of 2025).
Without additional financing, the Group’s current resources will support the gradual development of projects until the end of the first half of 2027. However, fully realizing both the value-creation potential of projects already under way within the Group (BACTEROMIC, EDOCERA, HYBOLIC) and the ability to generate new projects that could be pursued within new special-purpose vehicles will require additional funding.
We have a major opportunity ahead to maximize the value of the BACTEROMIC system – to obtain IVDR and FDA certifications and to initiate sales. Delivering on this plan will require additional funding that will, among other things, allow us to scale production capacity. A sale of the Bacteromic company that is advantageous for the Group also depends on our maintaining a secure negotiating position and sufficient flexibility regarding the terms of cooperation with potential strategic and institutional investors,” said Szymon Ruta, Vice President and Chief Financial Officer of Scope Fluidics.
“Our overarching goal is to build a dynamically growing global enterprise that consistently enhances shareholder value through new SPVs and regular strategic transactions. We are therefore focusing on investments that support operational scaling and long-term Group growth,” added Piotr Garstecki.
European and U.S. Patents
In April of this year, the European Patent Office granted Bacteromic a patent that gives the company exclusive commercial rights to the protected subject matter: a method for predicting microbial growth or inhibition in a phenotypic antibiotic-resistance test, a system for rapid antibiotic-resistance testing, and the use of a deep neural network to forecast such growth or inhibition, Scope Fluidics reported.
Additionally, in May of this year the United States Patent and Trademark Office granted Bacteromic a patent that confers exclusive commercial rights in the United States to the protected incubation-segment geometry within a microfluidic chip for microbiological testing. These tests cover both microbial identification and antibiotic-resistance assays, Scope Fluidics reported.
The company also holds a Chinese patent that grants exclusive commercial rights in China to the Bacteromic system’s protected method for determining microbial drug resistance in a phenotypic test.
